ifnγ- positive selected t-cells
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02007356)
Timeline
Indications
Mechanism of action
- unidentified adenovirusImmunity, passive
unidentified adenovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ifngamma- positive selected t-cells
- ifnγ- positive selected t-cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02346617 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2016 | Miltenyi Biotec, Inc., Samsung Medical Center, Sungkyunkwan University |
| NCT02007356 | Phase 2 | Dec 1, 2014 | University of Bern |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2016 |
| Samsung Medical Center | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2014 |
4 organizations
Page 1 / 1